Navigation Links
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Date:12/18/2007

ion facility and national resource was ostensibly to provide clinical grade vectors for clinical gene transfer protocols -- has closed its doors and announced the discontinuance of its programs, while all the world wonders. This same year, 2007, is the year that Rexin-G(R), the world's first and so far only targeted injectable genetic medicine that was designed, engineered, manufactured, validated, tested, and approved for the treatment of otherwise intractable metastatic cancers; the first and so far only one of the plethora of targeted biologics that exhibits broad spectrum anti-cancer activity when administered as a single therapeutic agent, advances alone toward product registration worldwide. So it appears that those of our academic colleagues should continue to teach and tell, while those who can actually do, should continue to do just that.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products and proprietary targeted delivery systems. Credited with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to "launch" its enabling platform technologies for the benefit of cancer patients worldwide. Meanwhile, rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the sale of its lead product to the Philippines and reciprocating ASEAN countries -- thus demonstrating the high growth potential of a small biotechnology company while maintaining the lowered risk profile of a biopharmaceutical company with a high-value, late-stage product.

More information: htt
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
2. Most Women With HIV and Their Health Care Providers Have Not Discussed How HIV Might Affect Them Differently Than Men
3. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
9. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
10. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... , March 30, 2015  MedAptus® today ... solution designed to simplify pre-care needs for busy ... intelligence to automatically assign patients to hospitalists or ... of care and other requirements such as ensuring ... ...
(Date:3/30/2015)... March 30, 2015  Orexigen Therapeutics, Inc. (Nasdaq: ... Cannell has joined as Chief Commercial Officer. ... Contrave® /Mysimba™ (naltrexone HCl / bupropion HCl extended ... global commercial strategy, assuming responsibilities previously held by ... commercial effort through the U.S. launch of Contrave, ...
(Date:3/30/2015)... Calif. , March 30, 2015  Cochlear ... has decided to leave Cochlear to join Valencia ... and friend, Jeff Greiner , who is ... Chief of Market Development and will be responsible ... of Valencia,s coin-sized neuromodulation ...
Breaking Medicine Technology:MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 2MedAptus Launches Automated Patient Assignment Solution for Hospitalists, Other Rounding Specialists 3Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 2Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 3Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 4Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 5Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 6Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 7Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 8Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 9Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 10Cochlear VP of U.S. Sales Jerry Schloffman Accepts Chief of Market Development Position at Valencia Technologies 2
(Date:3/30/2015)... 30, 2015 Follow us on ... to develop and establish chronic pain rehabilitation centers are ... the market is poised to benefit from the rise ... the increase in chronic health conditions such as Cancer, ... among others. While conventional treatment for pain management is ...
(Date:3/30/2015)... This report studies the global pharmacovigilance and ... of 2014 to 2019. This market is expected ... 2014 to 2019. , Further Inquiry @ ... pharmacovigilance and drug safety software market has been ... functionality, namely, adverse event reporting software, drug safety ...
(Date:3/30/2015)... March 30, 2015 Tel-Aviv – March ... prescription eyewear, announced the closing of $12.5 million in ... of the Viola Group. The funding will further GlassesUSA's ... leading player in the growing global market of online ... in 2009 by CEO Daniel Rothman, COO Eldad Rothman, ...
(Date:3/30/2015)... 30, 2015 On March 19th, 2015, ... home of the Detroit Lions, LiveToBeSober.org hosted the “Fighting ... pastors, ministers and bishops as well as other civic ... audience at the luncheon, including retired Detroit Lions wide ... Wickstrom and two survivors of their own personal battles ...
(Date:3/30/2015)... New York, New York (PRWEB) March 30, 2015 ... of its Top 10 Exotic Water Awards, with the top ... other winners are listed on the company’s website, along with ... Water’s website, exotic water, glacial water, spring water, mineral water ... Fiji water is one of the top exotic water ...
Breaking Medicine News(10 mins):Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2Health News:GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2
... study conducted by India and Canada which was carried out by ... decrease in the HIV prevalence. The data revealed that women ... of Tamil Nadu, Maharashtra, Karnataka and Andhra Pradesh had fallen from ... mainly seen in the four south Indian states. , ...
... Heart Journal has said that prayers do not seem to ... recently underwent cardiac bypass surgery. // On the contrary, prayers ... that their condition was far worse than thought. ... and the Baptist Memorial Health Care Corp, tracked the progress ...
... yet to receive AIDS medications from government-funded programs, which are ... to buy costly treatments, //according to an annual survey in ... states were also forced to cut down on the medications ... due to a shortage of funds. "The need for HIV-related ...
... babies who were given an aid to help them breathe ... The way was CNEP therapy - continuous negative-extrathoracic pressure. // ... researchers to the original trial in the early 1990s. ... Southall. ,The Nottingham researchers followed up 133 of ...
... Cephalon has been accorded a further six months of ... disorder treatment medication//, Provigil. ,Cephlaon had ... that entailed the provision of clinical studies data after ... ,Cephalon has settled the ‘provogil’patent infringement litigation with ...
... Australia’s crippled mental health services and community-based care centres. ... would triple for Australia's mental health services and hundreds ... the Government accepts the demands of a parliamentary committee. ... patients from institutions into the community. ...
Cached Medicine News:
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... Safety Infusion System is designed to ensure ... and the right dose. Available in four ... Safety Infusion System allows hospitals to choose ... their needs. DoseGuard™ dose limit technology and ...
... has an installed base of field-proven ... world. Hospital departments using Intermec media ... Supply, Admissions, Nursing Stations, Pharmacy, Medical ... labeling materials includes many products that ...
... Positive Patient Identification™ (PPI) system is an automated solution that identifies the patient, tying all critical information to ... ... ... ...
Medicine Products: